These findings, taken together, demonstrate that the percent of active-EGFR determined by HX103-based FACS assay correlates well with tumor sensitivity to EGFR-TKI, highlighting the potential utility of an EGFR-TKI-based probe in precision medicine trials to improve lung cancer patient management. The gene discussed is EGFR; the disease is lung cancer.